Vitiligo Study
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Vitiligo
Study Purpose
The purpose of the study is to evaluate whether the study drug, Ritlecitinib, is effective in managing vitiligo and if it is safe for human use. The study drug will be compared with a placebo, a study drug that does not contain any active ingredients, to find out if the study drug is better than the placebo for the study treatment of vitiligo.
Who Can Participate
Participants 18 years and older diagnosed with non-segmental vitiligo may be eligible for this study.
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
- UH IRB: SITE00001967
- StudyID: 2023-01170
- ClinicalTrials.gov: NCT05583526
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422